Buy Castle Biosciences: Re-rating Opportunity as DecisionDx-Melanoma Data Drives Adoption
Castle Biosciences is set up for a meaningful re-rating as prospective validation of its DecisionDx-Melanoma i31-SLNB test reduces clinical uncertainty for sentinel lymph node management. With a $699.6M market cap, low leverage, positive free cash flow, and oversold technicals, we outline a mid-term trade to capture upside while keeping strict risk…